Search Results - "Shimura, Yuji"

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum.

Authors: Okayama, Yusuke Takakuwa, Teruhito Shimura, Yuji et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-10. 10p.

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Authors: Fujino, Takahiro Okamoto, Haruya Nishiyama, Daichi et al.

Source: Leukemia & Lymphoma. Aug2025, Vol. 66 Issue 8, p1425-1436. 12p.

Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.

Authors: Onishi, Akio Miyagawa-Hayashino, Aya Okamoto, Haruya et al.

Source: Leukemia & Lymphoma. Aug2025, Vol. 66 Issue 8, p1413-1424. 12p.

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.

Authors: Shimazu, Yutaka Kanda, Junya Kosugi, Satoru et al.

Source: Scientific Reports. 3/29/2023, Vol. 13 Issue 1, p1-12. 12p.

Identification of non‐neutralizing anti‐factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency.

Authors: Souri, Masayoshi Osaki, Tsukasa Shimura, Yuji et al.

Source: Haemophilia. Mar2023, Vol. 29 Issue 2, p555-563. 9p. 1 Diagram, 2 Charts, 3 Graphs.

Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.

Authors: Takakuwa, Teruhito Yamamura, Ryosuke Ohta, Kensuke et al.

Source: European Journal of Haematology. Apr2021, Vol. 106 Issue 4, p555-562. 8p.

Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study.

Authors: Mizuhara, Kentaro Kobayashi, Tsutomu Nakao, Mitsushige et al.

Source: Cancer Medicine. Feb2023, Vol. 12 Issue 3, p3134-3144. 11p.

Acknowledgment to the Reviewers of Cells in 2022.

Source: Cells (2073-4409). Feb2023, Vol. 12 Issue 3, p375. 92p.

Mantle cell lymphoma with EBV‐positive Hodgkin and Reed–Sternberg‐like cells in a patient after autologous PBSCT: Phenotypically distinct but genetically related tumors.

Authors: Kanai, Risa Miyagawa‐Hayashino, Aya Shishido‐Hara, Yukiko et al.

Source: Pathology International. Jan2021, Vol. 71 Issue 1, p96-101. 6p.

Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.

Authors: Muramatsu, Ayako Kobayashi, Tsutomu Kawaji-Kanayama, Yuka et al.

Source: Leukemia & Lymphoma. Jul2022, Vol. 63 Issue 7, p1678-1685. 8p.

Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.

Authors: Matsumura‐Kimoto, Yayoi Tsukamoto, Taku Shimura, Yuji et al.

Source: Cancer Medicine. Jul2020, Vol. 9 Issue 14, p5185-5199. 15p.

Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.

Authors: Chinen, Yoshiaki Tanba, Kazuna Takagi, Ryo et al.

Source: Leukemia & Lymphoma. Dec2020, Vol. 61 Issue 14, p3378-3386. 9p.

Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.

Authors: Yamaguchi, Junko Chinen, Yoshiaki Takimoto-Shimomura, Tomoko et al.

Source: Leukemia & Lymphoma. Dec2019, Vol. 60 Issue 14, p3434-3441. 8p.

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.

Authors: Isa, Reiko Horinaka, Mano Tsukamoto, Taku et al.

Source: International Journal of Molecular Sciences. Mar2022, Vol. 23 Issue 6, p2919-2919. 18p.

Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System.

Authors: Inoue, Yu Okamoto, Haruya Miyashita, Akihiro et al.

Source: Oncology Letters. Feb2024, Vol. 27 Issue 2, pN.PAG-N.PAG. 1p.

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy.

Authors: Mizuno, Yoshimi Tsukamoto, Taku Kawata, Eri et al.

Source: Cancer Medicine. Mar2018, Vol. 7 Issue 3, p655-664. 10p.

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma.

Authors: Okamoto, Haruya Uoshima, Nobuhiko Muramatsu, Ayako et al.

Source: Diagnostics (2075-4418). Sep2021, Vol. 11 Issue 9, p1724. 1p.

Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma.

Authors: Fujibayashi, Yuto Isa, Reiko Nishiyama, Daichi et al.

Source: Cancers. Aug2020, Vol. 12 Issue 8, p2206-2206. 1p.

Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide.

Authors: Shimazu, Yutaka Kanda, Junya Kaneko, Hitomi et al.

Source: Therapeutic advances in hematology 12/13/2022; Vol. 13.

Journal Info: Publisher: Sage Publications Inc. ISSN: 2040-6207

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.

Authors: Onda, Yoshiyuki Kanda, Junya Kaneko, Hitomi et al.

Source: Therapeutic advances in hematology 6/24/2022; Vol. 13.

Journal Info: Publisher: Sage Publications Inc. ISSN: 2040-6207